Get started
Author

Guzman Alonso

Observed name: G. Alonso
ORCID: 0009-0005-6973-1981
Observed ORCID: 0009-0005-6973-1981
OpenAlex ID: A5082199705
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
2025 · Elena Garralda, Charles Abbott, et al. · Clinical Cancer Research · 7
PDF
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer
2026 · Benjamin Besse, Vivek Subbiah, et al. · Journal of Clinical Oncology · 4
1031P ANV419, a selective IL-2Rβ/γ agonist in patients with relapsed/refractory advanced solid tumors
2023 · E. Calvo, M. Joerger, et al. · Annals of Oncology · 1
PDF
Outcomes of Advanced Melanoma Patients (m-pts) Treated Beyond Progression with Immunotherapy (IO) in Early-Phase Clinical Trials (EFCT)
2025 · M.J. Lostes Bardaji, A. Mel Olano, et al. · EJC Skin Cancer
PDF
Non-invasive biomarkers for response and survival prediction in patients with advanced solid tumours treated with immune checkpoint inhibitors (ICIs)
2022 · K. Bernatowicz, M. Vieito, et al. · European Journal of Cancer
686P Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
2022 · O. Mirallas, D.H. Marmolejo Castaneda, et al. · Annals of Oncology
Works count: 6
Citation count: 12
H-index: 2
I10-index:
Year
Topic
Type